LOS ANGELES, CA, Jan. 11, 2018 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a clinical-stage developer of non-invasive electroceuticals for the treatment of central nervous system (CNS) disorders, today announced it is working with ShareIntel – Shareholder Intelligence Services to continue its commitment to protecting its shareholders and maximizing shareholder value. ShareIntel offers unprecedented access and insight into broker-dealer, clearing firm and shareholder position movement. ShareIntel utilizes a patented process called DRIL-DownTM to aggregate and analyze historic repository dataRead more
- Alternate Health Launches First Complete Ethereum Blockchain EMR / EHR
- NutraFuels, Inc. (NTFU) Provides 2017 Year End Financials Revenues Increase 694.6%
- Genprex Joins The Health Discovery Building At Dell Medical School To Help Drive Innovation For Health And Life Sciences
- Cannabics Pharmaceuticals Announces New Technology Patent
- Trump Cannabis Statements Leads Sugarmade to Positively Modify Business Growth Plans
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More